ECE2014 Poster Presentations Endocrine tumours and neoplasia (99 abstracts)
Gastro-entero-pancreatic neuroendocrine tumors (GEPNETs) – 10 year experience of one center
Ewelina Lewkowicz 1 , Malgorzata Trofimiuk-Müldner 1, , Dorota Pach 1, , Agnieszka Kieltyka 3 , Agnieszka Staszczak 2 , Anna Sowa-Staszczak 2 , Aleksandra Gilis-Januszewska 1, & Alicja Hubalewska-Dydejczyk 1,
1Chair and Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland; 2Endocrinology Department, Univesity Hospital in Krakow, Krakow, Poland; 3Chair of Epidemiology and Preventive Medicine, Krakow, Poland.
GEPNETs are rare tumors of very variable biology, particularly proliferative potential. Improved knowledge of the clinical course of disease may lead to proper identification of patients requiring more aggressive approach.
Aim: i) characteristics of GEP-NET patients of the Endocrinology Department, University Hospital in Krakow, Poland; ii) identification of factors influencing their 5-year survival.
Material and methods: Study included 122 patients of the Endocrinology Department (69 females, 53 males; mean age at diagnosis 57±15 years) living in Krakow or Krakow district, diagnosed with GEPNET between January 2002 and December 2011.The following factors were assessed: primary focus localization, grading (WHO), staging (AJCC/UICC), distant metastases at diagnosis, hormonal activity, and survival.
Results: The mean follow-up time was 4.9±2.8 years. The most frequent primary localization of GEPNET was small intestine (20%), followed by pancreas (19%), rectum (19%),stomach (17%), appendix (16%) and colon (9%). NET G1 accounted for 69%, NET G2 for 26%, NEC for 4%, MANEC for 1% of analyzed GEPNETs. NET G1 and G2 were included in staging analysis – 57% of patients were diagnosed at stage I. 77% of G1 tumors were diagnosed at stage I, majority of G2 GEPNETS at stage IV (58%), P<0.001.Distant metastases at diagnosis were found in 34% of patients. Disseminated disease was found in 78% of GEPNET originating from colon, 62% of pancreatic or small intestine GEPNETs, and in none of appendiceal GEPNETs (P<0.001). 90% of GEPNETs were non-functioning ones. The overall five year survival as 85%. In univariate analysis, higher stage according to AJCC/UICC, grade NET G2, metastases at diagnosis, were associated with poorer prognosis. In standardized multivariate models advanced stage and metastases were the independent risk factors of poor outcome.
Conclusions: Analysis of large groups of GEPNET patients followed up in one center allows the identification of factors influencing patients survival.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more